Coherus BioSciences Inc. (NASDAQ:CHRS) shares traded -7.14% lower at $4.68 on Wall Street last session.
In accordance with the data, 9 analysts cover Coherus BioSciences Inc. (NASDAQ:CHRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $7.00, we find $12.50. Given the previous closing price of $5.04, this indicates a potential upside of 148.02 percent. CHRS stock price is now -0.32% away from the 50-day moving average and -25.81% away from the 200-day moving average. The market capitalization of the company currently stands at $442.17M.
It has been rated a hold by 2 analysts and a buy by 6. Brokers who have rated the stock have averaged $12.75 as their price target over the next twelve months.
With the price target of $12, Citigroup recently initiated with Buy rating for Coherus BioSciences Inc. (NASDAQ: CHRS).
Insiders disposed of 56,868 shares of company stock worth roughly $0.27 million over the past 1 year. A total of 1.61% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CHRS stock. In total, there are 246 active investors with 92.78% ownership of the company’s stock.
Coherus BioSciences Inc. (NASDAQ: CHRS) opened at $4.9600 on Wednesday. During the past 12 months, Coherus BioSciences Inc. has had a low of $3.60 and a high of $10.99. The fifty day moving average price for CHRS is $4.7002 and a two-hundred day moving average price translates $6.2984 for the stock.
The latest earnings results from Coherus BioSciences Inc. (NASDAQ: CHRS) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, beating analysts’ expectations of -$0.48 by 0.1. This compares to -$0.65 EPS in the same period last year. The company reported revenue of $58.72 million for the quarter, compared to $60.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.39 percent. For the current quarter, analysts expect CHRS to generate $83.56M in revenue.
